← Leaderboards
Dan S Kaufman
University Of Minnesota Twin Cities
$9,522,879
Attributed
$18,112,285
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,112,285 · 11
By mechanism
U01$8,484,520 · 2
R01$7,472,419 · 4
R21$1,293,404 · 3
T32$779,338 · 1
P01$82,604 · 1
Top collaborators
- Jianyi Zhang7 shared
- Ezra Cohen6 shared
- Jill P. Mesirov6 shared
- Pablo Tamayo6 shared
- Bruce K Walcheck5 shared
- Daniel J. Garry3 shared
- Michael Kyba3 shared
- Jonathan M. Slack3 shared
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- Bruce K Walcheck$7,595,159
- Kathy L. Moser$9,726,693
- Daniel J Weisdorf$29,176,401
- Pankaj Gupta$1,793,782
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsStem CellsGeneticHuman Embryonic Stem CellMediatingIn VivoBaseResponseSignal PathwaySourceInnovationImmuneStem Cell BiologyClinical TrialsAntibodiesGene ExpressionTumorSolid NeoplasmMalignant NeoplasmsInduced Pluripotent Stem CellIn VitroAreaNatural Killer CellsMouse Model
Grant awards (42)
Cancer therapy by targeting innate immune cells in vivo using novel virus-like particles$222,998
R21 · FY2025 · CA · contact PI
Identification of Novel Regulators of Natural Killer Cell Activity$180,970
R21 · FY2022 · CA · contact PI
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States$942,132
U01 · FY2021 · CA
Identification of Novel Regulators of Natural Killer Cell Activity$221,186
R21 · FY2021 · CA · contact PI
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States$1,005,764
U01 · FY2020 · CA
Blocking NK cell shedding of CD16a to increase cancer cell killing$449,369
R01 · FY2020 · CA
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States$980,283
U01 · FY2019 · CA
Blocking NK cell shedding of CD16a to increase cancer cell killing$435,886
R01 · FY2019 · CA
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States$166,667
U01 · FY2019 · CA
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States$1,014,721
U01 · FY2018 · CA
Blocking NK cell shedding of CD16a to increase cancer cell killing$447,909
R01 · FY2018 · CA
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States$1,011,983
U01 · FY2017 · CA
Blocking NK cell shedding of CD16a to increase cancer cell killing$444,991
R01 · FY2017 · CA
Blocking NK cell shedding of CD16a to increase cancer cell killing$443,533
R01 · FY2016 · CA
Stem Cell Therapy for Myocardial Repair$421,480
R01 · FY2014 · HL
Osteogenic Repair from Human Pluripotent Stem Cells$352,052
R01 · FY2014 · DE · contact PI
Stem Cell Biology Training Program$181,400
T32 · FY2014 · HD · contact PI
Osteogenic Repair from Human Pluripotent Stem Cells$15,429
R01 · FY2014 · DE · contact PI
Stem Cell Therapy for Myocardial Repair$406,506
R01 · FY2013 · HL
Osteogenic Repair from Human Pluripotent Stem Cells$352,228
R01 · FY2013 · DE · contact PI
Stem Cell Biology Training Program$173,053
T32 · FY2013 · HD · contact PI
Stem Cell Therapy for Myocardial Repair$421,568
R01 · FY2012 · HL
Osteogenic Repair from Human Pluripotent Stem Cells$366,895
R01 · FY2012 · DE · contact PI
Stem Cell Biology Training Program$159,368
T32 · FY2012 · HD · contact PI
Midwestern Progenitor Cell Consortium$1,120,620
U01 · FY2011 · HL
Stem Cell Therapy for Myocardial Repair$420,295
R01 · FY2011 · HL
Osteogenic Repair from Human Pluripotent Stem Cells$380,135
R01 · FY2011 · DE · contact PI
Stem Cell Biology Training Program$177,616
T32 · FY2011 · HD · contact PI
Midwestern Progenitor Cell Consortium$1,109,850
U01 · FY2010 · HL
Hematopoietic Precursor Development from Human Embryonic Stem (ES) Cells$362,911
R01 · FY2010 · HL · contact PI
Stem Cell Biology Training Program$87,901
T32 · FY2010 · HD · contact PI
Midwestern Progenitor Cell Consortium$1,132,500
U01 · FY2009 · HL
Hematopoietic Precursor Development from Human Embryonic Stem (ES) Cells$362,911
R01 · FY2009 · HL · contact PI
Hematopoietic Precursor Development from Human Embryonic Stem (ES) Cells$189,158
R01 · FY2009 · HL · contact PI
Hematopoietic Precursor Development from Human Embryonic Stem (ES) Cells$362,911
R01 · FY2008 · HL · contact PI
Hematopoietic Precursor Development from Human Embryonic Stem (ES) Cells$113,250
R01 · FY2008 · HL · contact PI
Hematopoietic Precursor Development from Human Embryonic Stem (ES) Cells$356,182
R01 · FY2007 · HL · contact PI
Hematopoietic precursor development from human ES cells$366,820
R01 · FY2006 · HL · contact PI
Immunocompromised Mouse Core$82,604
P01 · FY2005 · CA
In Vivo Potential of Human ES Cell-Derived Blood Cells$222,750
R21 · FY2004 · HL
In Vivo Potential of Human ES Cell-Derived Blood Cells$222,750
R21 · FY2003 · HL
In Vivo Potential of Human ES Cell-Derived Blood Cells$222,750
R21 · FY2002 · HL